Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA?
- PMID: 23643835
- PMCID: PMC3729593
- DOI: 10.1016/j.exphem.2013.04.008
Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA?
Abstract
Myelodysplastic syndrome (MDS) is considered a hematopoietic stem cell disease that is characterized by abnormal hematopoietic differentiation and a high propensity to develop acute myeloid leukemia. It is mostly associated with advanced age, but also with prior cancer therapy and inherited syndromes related to abnormalities in DNA repair. Recent technologic advances have led to the identification of a myriad of frequently occurring genomic perturbations associated with MDS. These observations suggest that MDS and its progression to acute myeloid leukemia is a genomic instability disorder, resulting from a stepwise accumulation of genetic abnormalities. The notion is now emerging that the underlying mechanism of this disease could be a defect in one or more pathways that are involved in responding to or repairing damaged DNA. In this review, we discuss these pathways in relationship to a large number of studies performed with MDS patient samples and MDS mouse models. Moreover, in view of our current understanding of how DNA damage response and repair pathways are affected by age in hematopoietic stem cells, we also explore how this might relate to MDS development.
Copyright © 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Ting Zhou: none
Paul Hasty: none
Christi A. Walter: none
Alexander J.R. Bishop: none
Linda M. Scott: none
Vivienne I. Rebel: none
Figures


Similar articles
-
Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome.Int J Mol Sci. 2015 Jan 5;16(1):966-89. doi: 10.3390/ijms16010966. Int J Mol Sci. 2015. PMID: 25569081 Free PMC article. Review.
-
Physician Education: Myelodysplastic Syndrome.Oncologist. 1996;1(4):284-287. Oncologist. 1996. PMID: 10388004
-
Progressive genomic instability in the Nup98-HoxD13 model of MDS correlates with loss of the PIG-A gene product.Neoplasia. 2014 Aug;16(8):627-33. doi: 10.1016/j.neo.2014.07.004. Neoplasia. 2014. PMID: 25220590 Free PMC article.
-
Molecular and genetic features of myelodysplastic syndromes.Int J Lab Hematol. 2012 Jun;34(3):215-22. doi: 10.1111/j.1751-553X.2011.01390.x. Epub 2011 Dec 27. Int J Lab Hematol. 2012. PMID: 22212119 Review.
-
Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?Cancer Res. 2007 Sep 15;67(18):8762-71. doi: 10.1158/0008-5472.CAN-06-4807. Cancer Res. 2007. PMID: 17875717
Cited by
-
DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance.Chromosoma. 2014 Dec;123(6):545-61. doi: 10.1007/s00412-014-0482-9. Epub 2014 Aug 12. Chromosoma. 2014. PMID: 25112726 Review.
-
Development of cancer-initiating cells and immortalized cells with genomic instability.World J Stem Cells. 2015 Mar 26;7(2):483-9. doi: 10.4252/wjsc.v7.i2.483. World J Stem Cells. 2015. PMID: 25815132 Free PMC article. Review.
-
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.Pharmacogenomics J. 2018 May 22;18(3):444-449. doi: 10.1038/tpj.2017.48. Epub 2017 Dec 5. Pharmacogenomics J. 2018. PMID: 29205204
-
Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome.Int J Mol Sci. 2015 Jan 5;16(1):966-89. doi: 10.3390/ijms16010966. Int J Mol Sci. 2015. PMID: 25569081 Free PMC article. Review.
-
The value of serum IL-4 to predict the survival of MDS patients.Eur J Med Res. 2023 Jan 4;28(1):7. doi: 10.1186/s40001-022-00948-w. Eur J Med Res. 2023. PMID: 36600245 Free PMC article.
References
-
- Nilsson L, Eden P, Olsson E, et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood. 2007;110:3005–3014. - PubMed
-
- Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:692–701. - PubMed
-
- Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous